AVTR
Avantor, Inc. NYSE Listed May 17, 2019$8.32
Mkt Cap $5.7B
52w Low $7.26
12.2% of range
52w High $15.93
50d MA $8.09
200d MA $11.14
P/E (TTM)
-10.2x
EV/EBITDA
81.8x
P/B
1.0x
Debt/Equity
0.7x
ROE
-9.9%
P/FCF
15.7x
RSI (14)
—
ATR (14)
—
Beta
1.00
50d MA
$8.09
200d MA
$11.14
Avg Volume
10.6M
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Radnor Corporate Center · Radnor, PA 19087 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 0.16 | 0.17 | +6.2% | 7.85 | +0.1% | +3.2% | +1.4% | +1.8% | +2.5% | +7.4% | — |
| Feb 11, 2026 | TNS | 0.21 | 0.22 | +4.8% | 9.64 | -1.5% | -5.2% | -4.6% | -6.1% | -3.8% | -4.5% | — |
| Oct 29, 2025 | TNS | 0.22 | 0.22 | -2.1% | 11.58 | -2.2% | -4.6% | +2.1% | +0.9% | +0.0% | +0.0% | — |
| Aug 1, 2025 | TNS | 0.25 | 0.24 | -4.0% | 11.36 | +0.4% | -0.5% | +2.5% | -1.6% | +0.2% | +1.2% | — |
| Apr 25, 2025 | TNS | 0.23 | 0.23 | -0.6% | 12.93 | -0.1% | -3.4% | -1.9% | +0.5% | +0.2% | -0.5% | — |
| Feb 7, 2025 | TNS | 0.25 | 0.27 | +8.0% | 19.16 | +1.8% | -0.8% | -4.0% | -5.8% | -5.5% | -6.7% | — |
| Oct 25, 2024 | TNS | 0.25 | 0.26 | +2.1% | 22.43 | +1.5% | +0.9% | +0.4% | +0.1% | -0.3% | -0.5% | — |
| Jul 26, 2024 | TNS | 0.23 | 0.25 | +7.6% | 25.60 | -0.2% | +2.5% | +8.0% | +4.5% | +3.5% | +0.0% | — |
| Apr 26, 2024 | TNS | 0.20 | 0.22 | +9.5% | 23.94 | -0.4% | +0.6% | +1.2% | +2.0% | +1.6% | +3.3% | — |
| Feb 14, 2024 | TNS | 0.22 | 0.25 | +13.6% | 24.40 | +0.0% | -1.4% | -2.6% | -1.4% | +0.0% | +0.8% | — |
| Oct 27, 2023 | TNS | 0.25 | 0.25 | +0.0% | 17.83 | +0.6% | -3.8% | -2.2% | -2.4% | +2.1% | +3.0% | — |
| Jul 28, 2023 | TNS | 0.29 | 0.28 | -3.4% | 21.28 | -1.4% | -3.3% | -1.8% | -1.2% | -3.2% | -2.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Evercore ISI | Maintains | In Line → In Line | — | $7.85 | $7.86 | +0.1% | +3.2% | +1.4% | +1.8% | +2.5% | +7.4% |
| Apr 30 | Citigroup | Maintains | Neutral → Neutral | — | $7.85 | $7.86 | +0.1% | +3.2% | +1.4% | +1.8% | +2.5% | +7.4% |
| Apr 15 | Barclays | Maintains | Underweight → Underweight | — | $8.20 | $8.28 | +1.0% | +2.1% | +0.7% | +3.9% | +3.7% | +4.0% |
| Apr 6 | Evercore ISI | Maintains | In Line → In Line | — | $7.90 | $7.78 | -1.5% | +1.0% | +1.3% | +1.3% | +0.3% | +0.0% |
| Mar 6 | Barclays | Downgrade | Equal Weight → Underweight | — | $8.52 | $8.26 | -3.1% | -4.1% | -4.3% | -4.3% | -2.7% | -7.3% |
| Feb 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $9.14 | $9.52 | +4.2% | +0.7% | -1.0% | +1.4% | +0.8% | -1.2% |
| Feb 12 | Barclays | Maintains | Equal Weight → Equal Weight | — | $9.64 | $9.50 | -1.5% | -5.2% | -4.6% | -6.1% | -3.8% | -4.5% |
| Feb 12 | Citigroup | Maintains | Neutral → Neutral | — | $9.64 | $9.50 | -1.5% | -5.2% | -4.6% | -6.1% | -3.8% | -4.5% |
| Jan 7 | TD Cowen | Maintains | Hold → Hold | — | $12.27 | $12.25 | -0.2% | -1.5% | -1.7% | +1.1% | +0.1% | +2.7% |
| Jan 5 | Evercore ISI | Downgrade | Outperform → In Line | — | $11.46 | $11.28 | -1.6% | +3.8% | +7.1% | +5.4% | +5.2% | +8.3% |
| Dec 17 | Jefferies | Downgrade | Hold → Underperform | — | $11.20 | $10.96 | -2.1% | -0.9% | -1.2% | +0.6% | +0.4% | +0.6% |
| Oct 30 | Barclays | Downgrade | Overweight → Equal Weight | — | $11.58 | $11.33 | -2.2% | -4.6% | +2.1% | +0.9% | +0.0% | +0.0% |
| Oct 30 | JP Morgan | Downgrade | Overweight → Neutral | — | $11.58 | $11.33 | -2.2% | -4.6% | +2.1% | +0.9% | +0.0% | +0.0% |
| Oct 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $11.58 | $11.33 | -2.2% | -4.6% | +2.1% | +0.9% | +0.0% | +0.0% |
| Oct 24 | Baird | Maintains | Outperform → Outperform | — | $15.46 | $15.61 | +1.0% | -0.4% | -2.3% | -2.5% | -25.1% | -28.5% |
| Oct 16 | Raymond James | Maintains | Outperform → Outperform | — | $13.87 | $14.10 | +1.7% | +5.0% | +6.6% | +9.4% | +12.5% | +9.3% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $13.67 | $13.71 | +0.3% | +0.7% | +4.5% | +3.1% | -1.5% | +0.6% |
| Aug 4 | Baird | Maintains | Outperform → Outperform | — | $11.36 | $11.41 | +0.4% | -0.5% | +2.5% | -1.6% | +0.2% | +1.2% |
| Aug 4 | Raymond James | Maintains | Outperform → Outperform | — | $11.36 | $11.41 | +0.4% | -0.5% | +2.5% | -1.6% | +0.2% | +1.2% |
| Aug 4 | Barclays | Maintains | Overweight → Overweight | — | $11.36 | $11.41 | +0.4% | -0.5% | +2.5% | -1.6% | +0.2% | +1.2% |
| Aug 4 | RBC Capital | Maintains | Outperform → Outperform | — | $11.36 | $11.41 | +0.4% | -0.5% | +2.5% | -1.6% | +0.2% | +1.2% |
| Aug 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.36 | $11.41 | +0.4% | -0.5% | +2.5% | -1.6% | +0.2% | +1.2% |
| Aug 4 | Stifel | Maintains | Hold → Hold | — | $11.36 | $11.41 | +0.4% | -0.5% | +2.5% | -1.6% | +0.2% | +1.2% |
| Aug 4 | Evercore ISI | Maintains | Outperform → Outperform | — | $11.36 | $11.41 | +0.4% | -0.5% | +2.5% | -1.6% | +0.2% | +1.2% |
| Aug 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.36 | $11.41 | +0.4% | -0.5% | +2.5% | -1.6% | +0.2% | +1.2% |
| Aug 4 | JP Morgan | Maintains | Overweight → Overweight | — | $11.36 | $11.41 | +0.4% | -0.5% | +2.5% | -1.6% | +0.2% | +1.2% |
| Jul 28 | Baird | Maintains | Outperform → Outperform | — | $14.21 | $14.30 | +0.6% | -1.5% | -1.4% | -2.9% | -5.4% | -20.1% |
| Apr 29 | Goldman Sachs | Downgrade | Buy → Neutral | — | $12.49 | $12.41 | -0.6% | +1.6% | +4.0% | +3.8% | +3.0% | +1.1% |
| Apr 28 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $12.93 | $12.92 | -0.1% | -3.4% | -1.9% | +0.5% | +0.2% | -0.5% |
| Apr 28 | Barclays | Maintains | Overweight → Overweight | — | $12.93 | $12.92 | -0.1% | -3.4% | -1.9% | +0.5% | +0.2% | -0.5% |
| Apr 28 | Stifel | Downgrade | Buy → Hold | — | $12.93 | $12.92 | -0.1% | -3.4% | -1.9% | +0.5% | +0.2% | -0.5% |
| Apr 28 | Baird | Maintains | Outperform → Outperform | — | $12.93 | $12.92 | -0.1% | -3.4% | -1.9% | +0.5% | +0.2% | -0.5% |
| Apr 28 | RBC Capital | Maintains | Outperform → Outperform | — | $12.93 | $12.92 | -0.1% | -3.4% | -1.9% | +0.5% | +0.2% | -0.5% |
| Apr 17 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.25 | $15.17 | -0.5% | -1.0% | -1.9% | +0.2% | +1.4% | +1.6% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $15.89 | $15.42 | -3.0% | -7.5% | -4.2% | -2.1% | -3.1% | -4.0% |
| Mar 4 | Citigroup | Maintains | Neutral → Neutral | — | $15.87 | $15.70 | -1.1% | -2.3% | -0.8% | +1.9% | +10.3% | +8.9% |
| Feb 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $19.16 | $19.50 | +1.8% | -0.8% | -4.0% | -5.8% | -5.5% | -6.7% |
| Feb 10 | Barclays | Maintains | Overweight → Overweight | — | $19.16 | $19.50 | +1.8% | -0.8% | -4.0% | -5.8% | -5.5% | -6.7% |
| Feb 10 | Stifel | Maintains | Buy → Buy | — | $19.16 | $19.50 | +1.8% | -0.8% | -4.0% | -5.8% | -5.5% | -6.7% |
| Feb 10 | RBC Capital | Maintains | Outperform → Outperform | — | $19.16 | $19.50 | +1.8% | -0.8% | -4.0% | -5.8% | -5.5% | -6.7% |
| Feb 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $19.16 | $19.50 | +1.8% | -0.8% | -4.0% | -5.8% | -5.5% | -6.7% |
| Feb 10 | Raymond James | Maintains | Outperform → Outperform | — | $19.16 | $19.50 | +1.8% | -0.8% | -4.0% | -5.8% | -5.5% | -6.7% |
| Feb 3 | Barclays | Maintains | Overweight → Overweight | — | $22.28 | $21.94 | -1.5% | -1.8% | -1.2% | -1.3% | -2.6% | -14.0% |
| Jan 21 | Raymond James | Maintains | Outperform → Outperform | — | $22.11 | $22.23 | +0.5% | -1.5% | -0.0% | -1.1% | -0.2% | +1.7% |
| Jan 17 | UBS | Downgrade | Buy → Neutral | — | $22.57 | $22.21 | -1.6% | -2.0% | -3.5% | -2.1% | -3.1% | -2.3% |
| Oct 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $22.43 | $22.77 | +1.5% | +0.9% | +0.4% | +0.1% | -0.3% | -0.5% |
| Oct 28 | Baird | Maintains | Outperform → Outperform | — | $22.43 | $22.77 | +1.5% | +0.9% | +0.4% | +0.1% | -0.3% | -0.5% |
| Oct 25 | Barclays | Maintains | Overweight → Overweight | — | $23.27 | $22.65 | -2.7% | -3.6% | -2.7% | -3.2% | -3.5% | -3.9% |
| Oct 8 | UBS | Maintains | Buy → Buy | — | $24.99 | $24.64 | -1.4% | -0.8% | -0.9% | -2.1% | -1.0% | +0.3% |
| Sep 26 | RBC Capital | Maintains | Outperform → Outperform | — | $25.67 | $26.10 | +1.7% | +1.5% | +0.6% | +0.8% | -1.0% | -0.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Dingemans SimonDir | — | Buy | 25,000 | $8.14 | $204K | 25,000 | +4.72% | — |
8-K
Avantor, Inc. -- 8-K Filing
Avantor maintained its full-year 2026 guidance despite generating $25 million in cash flow during Q1, suggesting management confidence in operational performance amid ongoing execution.
Apr 29
8-K · 5.02
!!! Very High
Avantor, Inc. -- 8-K 5.02: Executive Change
Avantor appointed Ludovic Brellier as Executive Vice President, expanding its leadership team to strengthen operational oversight and strategic execution.
Apr 23
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A new CFO with GE and industrial manufacturing experience joins Avatars, potentially signaling improved financial controls and credibility with investors in capital-intensive operations.
Apr 1
8-K · 5.02
!!! Very High
Avantor, Inc. -- 8-K 5.02: Executive Change
Avantor appointed Sanjeev Mehra as a director effective December 4, 2025, expanding its board composition and potentially bringing new expertise to the life sciences services company's governance.
Feb 25
8-K · 5.02
!!! Very High
Avantor, Inc. -- 8-K 5.02: Executive Change
Avantor appoints Simon Dingemans as director effective January 2, 2026, potentially strengthening board oversight of the life sciences and materials supplier.
Feb 25
8-K · 7.01
! Medium
Avantor, Inc. -- 8-K 7.01: Regulation FD Disclosure
Avantor issued a press release on February 11, 2026, disclosing material information to investors under Regulation FD requirements.
Feb 11
Data updated apr 24, 2026 8:04pm
· Source: massive.com